Question 1

What is Emalex Biosciences?

Accepted Answer

Emalex Biosciences is a Entity.

Question 2

How often does Emalex Biosciences appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 33 articles.

Question 3

When was Emalex Biosciences first tracked by Ergen?

Accepted Answer

First tracked on Apr 29, 2026.

Question 4

When was Emalex Biosciences last mentioned in news?

Accepted Answer

Last active on Jul 20, 2026.

Question 5

What is Emalex Biosciences's current news sentiment?

Accepted Answer

Aggregate sentiment score: 35 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Emalex Biosciences in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Emalex Biosciences?

Accepted Answer

Teva acquires Emalex Biosciences for ecopipam (Jun 10, 2026, 8 articles).

Question 8

How did the "Teva acquires Emalex Biosciences for ecopipam" event impact Emalex Biosciences?

Accepted Answer

Emalex Biosciences was acquired by Sun Pharma for $700 million upfront, with potential for additional milestone payments and royalties. This acquisition validates its work in developing Ecopipam for Tourette syndrome.

Question 9

How did the "Eli Lilly acquires AtaiBeckley for $2.8B" event impact Emalex Biosciences?

Accepted Answer

Emalex Biosciences was acquired by Eli Lilly earlier in 2026, a biotech company.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.